ATRX Loss Sensitizes Glioma Cells to RTK and PDGFR Inhibitor
2026-05-20
Pladevall-Morera et al. identify that high-grade glioma cells lacking ATRX are more vulnerable to multi-targeted RTK and PDGFR inhibitors, including agents such as Nintedanib. This finding offers a potential stratification strategy for improving therapeutic efficacy in aggressive gliomas and highlights the value of incorporating ATRX mutation status in clinical trial analyses.
Strategic Use of Aβ42 Peptide: Mechanisms and Translational
2026-05-20
This thought-leadership article explores the mechanistic role of Amyloid β-Peptide (1-42) (Aβ42) in Alzheimer's pathology, highlighting its utility in neurotoxicity and microglial activation assays. By bridging molecular insights with strategic guidance, we inform translational researchers on optimizing experimental design, selecting high-quality reagents, and anticipating the next wave of neurodegeneration research.
HSP90 Inhibition Destabilizes METTL3 and Suppresses MYC in C
2026-05-19
This study uncovers a mechanism in which HSP90 stabilizes the m6A methyltransferase METTL3 in colorectal cancer (CRC), thereby promoting MYC expression. Inhibiting HSP90 using 17-AAG accelerates METTL3 degradation, reduces MYC mRNA stability, and impairs cancer cell proliferation, highlighting the HSP90-METTL3 axis as a therapeutic target.
EZ Cap™ Cas9 mRNA (m1Ψ): Cap1-Structured mRNA for Genome Edi
2026-05-19
EZ Cap™ Cas9 mRNA (m1Ψ) is a Cap1-structured, N1-Methylpseudo-UTP-modified mRNA designed for efficient and precise CRISPR-Cas9 genome editing. This reagent enhances mRNA stability, translation efficiency, and suppresses innate immune activation in mammalian cells. APExBIO’s R1014 product is validated for high-specificity gene editing workflows.
Translating Cathepsin B Inhibition: CA-074 Me in Necroptosis
2026-05-18
This thought-leadership article synthesizes mechanistic advances in lysosomal membrane permeabilization, the execution of necroptosis, and the translational potential of CA-074 Me as a cathepsin B inhibitor. It bridges foundational cell death biology with actionable guidance for researchers pursuing apoptosis, lysosomal enzyme inhibition, and inflammation models. Drawing on landmark evidence and building upon prior CA-074 Me-focused content, this piece uniquely situates product intelligence within a rigorous, forward-thinking research strategy.
Improving In Vitro Evaluation of Anti-Cancer Drug Responses
2026-05-18
Schwartz's dissertation advances in vitro drug testing by distinguishing between growth inhibition and cell death, revealing nuanced drug response dynamics in cancer models. These insights refine evaluation strategies for angiogenesis inhibitors and improve translational relevance in preclinical research.
Transmission Dynamics of Carbapenemase Genes in CREC, China
2026-05-17
This study characterizes the molecular epidemiology and transfer mechanisms of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae from Guangdong hospitals during the COVID-19 pandemic. The findings highlight high rates of multidrug resistance and the efficient horizontal spread of resistance genes, informing future surveillance and intervention strategies.
Ceftolozane/Tazobactam: Novel Strategies Against Resistant G
2026-05-16
The reviewed paper details the pharmacological profile, clinical efficacy, and resistance-breaking features of ceftolozane/tazobactam, a new cephalosporin/beta-lactamase inhibitor combination. Its differentiation lies in potent activity against multidrug-resistant gram-negative pathogens, especially Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae, marking significant progress in the management of complicated intraabdominal and urinary tract infections.
RG108 DNA Methyltransferase Inhibitor: Protocols & Use Cases
2026-05-15
RG108 is a benchmark DNA methyltransferase inhibitor for reversible, non-cytotoxic epigenetic modulation in cancer and stem cell research. Explore evidence-based protocols, unique workflow enhancements, and troubleshooting strategies that unlock the full potential of this small molecule for gene regulation studies.
Sisomicin: Optimizing Aminoglycoside Antibiotic Workflows in
2026-05-15
Sisomicin, a potent aminoglycoside antibiotic, excels in both Gram-negative and Gram-positive bacterial infection models by targeting bacterial protein synthesis at the 30S ribosomal subunit. This guide delivers actionable protocols, troubleshooting tips, and workflow enhancements, drawing on the latest in vitro assay innovations and APExBIO’s trusted supply chain.
U3 snoRNA-DDX21 Interplay Regulates Mitosis via Perichromoso
2026-05-14
This study uncovers a crucial regulatory relationship between U3 snoRNA and the helicase DDX21 in the perichromosomal region during mitosis. By elucidating their interdependent localization and impact on phase-separated chromosomal assemblies, the work redefines the functional significance of non-coding RNAs and RNA-binding proteins in mitotic progression.
SGI-1027: DNA Methyltransferase Inhibitor for Cancer Epigene
2026-05-14
SGI-1027 empowers researchers to precisely inhibit DNA methylation, reactivate silenced tumor suppressor genes, and overcome resistance pathways in cancer models. Its unique mechanism and robust workflow compatibility make it a go-to choice for translational epigenetics and combination therapy exploration.
Deracoxib: Selective COX-2 Inhibitor for Advanced Inflammati
2026-05-13
Deracoxib, a highly selective COX-2 inhibitor, offers robust anti-inflammatory and antitumor capabilities for precise pain and inflammation research. Its synergy with chemotherapeutics and reproducible performance in canine models make it a cornerstone for advanced workflow design and troubleshooting.
(-)-JQ1 Stereoisomer: Rigorous Controls in BET Bromodomain R
2026-05-13
Explore the scientific significance of (-)-JQ1 as a negative control in BET bromodomain studies. This article uniquely analyzes the compound's role in assay design, referencing cutting-edge cancer biology research and highlighting best practices for rigorous epigenetics research.
Nintedanib (BIBF 1120): Optimizing Antiangiogenic Research W
2026-05-12
Nintedanib (BIBF 1120) enables robust, reproducible antiangiogenic and antifibrotic assays across cancer and fibrosis models. This article translates recent high-impact findings into actionable protocols, advanced troubleshooting, and strategic guidance for leveraging APExBIO’s trusted formulation in both cell and animal studies.
556 records 18/38 page Previous Next First page 上5页 1617181920 下5页 Last page